Wanbury Ltd.
Fundamentals
- Market cap
- ₹959 cr
- P/E
- 22.30×
- ROE
- 51.51%
- Debt / equity
- 2.92
- 52-week range
- 161.50 — 315.20
Wanbury Ltd.
Latest quarter · Jun 2025
Strength & growth
The timeline — 6 notes on Wanbury Ltd.
July 2026
- 20 Jul 26 · 4:15 PM IST Lead Lead · Micro cap
Wanbury's Tanuku API plant lands six USFDA observations
Routine cGMP inspection ends with Form 483 citing six observations at the Tanuku facility. Company says it will respond; the same site recently passed a TGA audit.
- 15 Jul 26 · 5:45 PM IST Alert Alert · Micro cap
Wanbury pays off ₹180 cr NCDs five years early
Board approves early redemption in full of 12.5% secured NCDs originally maturing in 2030, wiping out a substantial debt ahead of schedule.
- 09 Jul 26 · 10:39 AM IST Lead Lead · Credit · Micro cap
Wanbury's 24% pledge release removes forced-sale overhang
Catalyst Trusteeship released 85.2 lakh shares held by Expert Chemicals, cutting encumbered stake from 34.93% to 10.54%. A rare move for a micro-cap that signals creditor confidence.
June 2026
- 10 Jun 26 · 12:40 PM IST Lead Lead · Micro cap
Wanbury clears TGA inspection, nears entry into Australia with three APIs
A successful TGA quality check at Tanuku puts Wanbury one step away from shipping three new active ingredients to Australia. For a ₹913 cr market-cap drugmaker, the regulatory clearance opens a new export market.
- 09 Jun 26 · 1:32 PM IST Brief Brief · Micro cap
Wanbury files for new API markets in Malaysia, Singapore, Korea
The micro-cap drug-maker is expanding its regulatory filings for two active pharmaceutical ingredients across four new geographies.
- 02 Jun 26 · 12:24 PM IST Brief Brief · Earnings · Micro cap
Wanbury's full-year profit jumps 117% on better mix and procurement savings
Net profit surged to ₹66.1 crore for FY26, though a West Asia-related export disruption dented the final quarter.